Protocol: ADX-324-01. A phase I, single ascending dose study in healthy volunteers and an expansion cohort in patients with hereditary angioedemia to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ADX-324 (Interim Analysis #2)